Learn More  
About BT

Severe Asthma Impacted My LifeDo you know how much it impacts yours?

Who Is BT For?

Bronchial Thermoplasty is for severe asthma patients 18 years or older whose asthma not well controlled with taking multiple asthma medications including ICS and LABA such as Advair™, Symbicort™, and Dulera™ and one or more of the following:

  • Still having severe asthma attacks
  • Adjusting your lifestyle to avoid asthma triggers
  • Absent from work, school or daily activities because of your severe asthma

BT Is Not Right For Patients Who:

  • Are under 18 years old
  • Have a pacemaker, internal defibrillator, or other implantable electronic device
  • Have known sensitivity to medications required to perform bronchoscopy, including lidocaine, atropine and benzodiazepines
  • Have previously been treated with BT

Have Questions About Bronchial Thermoplasty?

Talk with your doctor or speak with a trained healthcare professional who can help you.
Monday-Friday 9:00 AM - 8:00 PM Eastern

Call (888) 272-8440 

What to Expect:

BT is not a cure for your severe asthma but may help to improve your asthma-related quality of life. It's different for each patient but clinical trials showed that many patients experienced reductions in severe asthma attacks, ER visits, and hospitalizations for respiratory symptoms, and fewer days lost from work, school, and other daily activities due to severe asthma. 

The Alair™ Bronchial Thermoplasty System is indicated for the treatment of severe persistent asthma in patients 18 years and older whose asthma is not well controlled with inhaled corticosteroids and long-acting beta-agonists.

As with any procedure, there are risks, and individual results may vary. The most common adverse event of BT is a temporary worsening of respiratory-related symptoms. These events typically occur within one day of the BT procedure and usually resolve within a week with standard care. There is a small risk (3.4% per procedure) that symptoms may require hospitalization.1


  1. Castro M, et al, for the AIR2 Trial Study Group. Am J Respir Crit Care Med. 2010;181:116-124.